Here's a fun fact about American healthcare: drugmakers are about to raise prices on more than 350 branded medicines, and they're doing it right in the middle of a political moment where everyone from the White House down is supposedly laser-focused on bringing drug costs down. The irony is not lost on anyone.
According to exclusive data from healthcare research firm 3 Axis Advisors reported by Reuters, pharmaceutical companies are preparing to bump up U.S. prices on at least 350 branded drugs starting in 2026. We're talking vaccines for COVID-19, RSV, and shingles, plus major cancer therapies. The planned increases already exceed the 250 drugs flagged at the same point last year, so the trend is heading in the wrong direction if you're a patient trying to afford your medications.
The median increase sits at about 4%, which is roughly consistent with what we saw for 2025. Now, these figures reflect list prices, not what insurers actually pay after rebates to pharmacy benefit managers and other behind-the-scenes discounts. But list prices still matter quite a bit for uninsured patients and people with high-deductible plans who pay out of pocket.
A Handful of Price Cuts
It's not all bad news, though the good news is pretty slim. About nine drugs are getting price cuts, including a substantial one for Boehringer Ingelheim's diabetes drug Jardiance and three related treatments, which will see reductions of more than 40%.
Jardiance is actually one of the 10 drugs for which the U.S. government negotiated lower prices for the Medicare program beginning in 2026. Boehringer Ingelheim and Eli Lilly (LLY) agreed to slash the drug's price by roughly two-thirds. That's a genuinely significant cut, and it shows what happens when the government flexes its negotiating muscle.
The context here matters: U.S. patients currently pay significantly more for prescription medicines than patients in other developed countries. President Donald Trump has repeatedly pointed to this gap while pressuring drugmakers to lower prices, but the broader pattern suggests those appeals aren't translating into widespread action.
Pricing Deals Aren't Stopping the Hikes
The wave of increases is happening even though the Trump administration recently struck pricing deals with 14 manufacturers covering certain drugs sold through Medicaid and to cash-paying consumers. The companies that signed on include Pfizer (PFE), Sanofi (SNY), Boehringer Ingelheim, Novartis (NVS), and GSK (GSK), and all of them still plan to raise prices on other products starting January 1.
Pfizer is leading the pack with planned hikes on roughly 80 drugs, including cancer therapy Ibrance, migraine treatment Nurtec, and COVID-19 drug Paxlovid. Most of these increases stay below 10%, but the company is planning a 15% jump for its COVID vaccine Comirnaty. Some low-cost hospital drugs face even steeper increases.
The Company Line
When asked about the pricing strategy, Pfizer told Reuters that its average list price increases for innovative medicines and vaccines remain below overall inflation. The company says the hikes are necessary to support research and rising business costs, which is the standard industry explanation.
It's worth noting that pharmaceutical companies operate in a weird economic environment where they need to fund extremely expensive research and development while also answering to shareholders who expect growth. The problem is that this tension gets resolved by raising prices on people who literally need these drugs to stay alive or manage chronic conditions. The system works great for everyone except patients, which is why this issue keeps coming up in election after election without getting meaningfully resolved.
The fact that price increases are outpacing last year's numbers, even with heightened political attention on drug pricing, suggests that public pressure and voluntary agreements have their limits. Real change would probably require structural reforms to how drugs are priced and reimbursed in the United States, but that's a much heavier lift than striking deals with individual manufacturers.
